255 related articles for article (PubMed ID: 24162786)
1. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.
Musso A; Catellani S; Canevali P; Tavella S; Venè R; Boero S; Pierri I; Gobbi M; Kunkl A; Ravetti JL; Zocchi MR; Poggi A
Haematologica; 2014 Jan; 99(1):131-9. PubMed ID: 24162786
[TBL] [Abstract][Full Text] [Related]
2. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.
Zocchi MR; Catellani S; Canevali P; Tavella S; Garuti A; Villaggio B; Zunino A; Gobbi M; Fraternali-Orcioni G; Kunkl A; Ravetti JL; Boero S; Musso A; Poggi A
Blood; 2012 Feb; 119(6):1479-89. PubMed ID: 22167753
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas.
Chaperot L; Delfau-Larue MH; Jacob MC; Molens JP; Roussel B; Agrawal S; Farcet JP; Gressin R; Sotto JJ; Bensa JC; Plumas J
Exp Hematol; 1999 Jul; 27(7):1185-93. PubMed ID: 10390194
[TBL] [Abstract][Full Text] [Related]
4. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases.
Sheibani K; Winberg CD; van de Velde S; Blayney DW; Rappaport H
Am J Pathol; 1987 Apr; 127(1):27-37. PubMed ID: 3105322
[TBL] [Abstract][Full Text] [Related]
5. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
6. The feature of distribution and clonality of TCR γ/δ subfamilies T cells in patients with B-cell non-Hodgkin lymphoma.
Wang L; Xu M; Wang C; Zhu L; Hu J; Chen S; Wu X; Li B; Li Y
J Immunol Res; 2014; 2014():241246. PubMed ID: 24963496
[TBL] [Abstract][Full Text] [Related]
7. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic analysis by flow cytometry of surface immunoglobulin light chains and B and T cell antigens in lymph nodes involved with non-Hodgkin's lymphoma.
Liendo C; Danieu L; Al-Katib A; Koziner B
Am J Med; 1985 Oct; 79(4):445-54. PubMed ID: 3931469
[TBL] [Abstract][Full Text] [Related]
9. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
Varesano S; Zocchi MR; Poggi A
Front Immunol; 2018; 9():998. PubMed ID: 29867975
[TBL] [Abstract][Full Text] [Related]
11. T-lymphocyte subpopulations in B-cell-derived non-Hodgkin's lymphomas and Hodgkin's disease.
Knowles DM; Halper JP; Jakobiec FA
Cancer; 1984 Aug; 54(4):644-51. PubMed ID: 6234982
[TBL] [Abstract][Full Text] [Related]
12. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines.
Delabie J; Ceuppens JL; Vandenberghe P; de Boer M; Coorevits L; De Wolf-Peeters C
Blood; 1993 Nov; 82(9):2845-52. PubMed ID: 7693051
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
14. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
15. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines.
Cimini E; Piacentini P; Sacchi A; Gioia C; Leone S; Lauro GM; Martini F; Agrati C
Int J Immunopathol Pharmacol; 2011; 24(1):139-48. PubMed ID: 21496396
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.
Petrini I; Pacini S; Petrini M; Fazzi R; Trombi L; Galimberti S
Eur J Clin Invest; 2009 Sep; 39(9):813-8. PubMed ID: 19522834
[TBL] [Abstract][Full Text] [Related]
18. Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines.
Anichini A; Mortarini R; Romagnoli L; Baldassari P; Cabras A; Carlo-Stella C; Gianni AM; Di Nicola M
Blood; 2006 Jan; 107(2):602-9. PubMed ID: 16150945
[TBL] [Abstract][Full Text] [Related]
19. Stress immunity in lymphomas: mesenchymal cells as a target of therapy.
Poggi A; Zocchi MR
Front Biosci (Landmark Ed); 2014 Jan; 19(2):281-90. PubMed ID: 24389184
[TBL] [Abstract][Full Text] [Related]
20. Induction of immunoglobulin secretion in follicular non-Hodgkin's lymphomas: role of immunoregulatory T cells.
Braziel RM; Sussman E; Jaffe ES; Neckers LM; Cossman J
Blood; 1985 Jul; 66(1):128-34. PubMed ID: 3159441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
